Ajanta Pharma reported a 20% increase in Profit After Tax (PAT) for Q2 FY26, reaching ₹260 cr. Revenue from operations grew by 14% to ₹1,354 cr. The Board approved an interim dividend of ₹28 per share. Excluding forex losses, EBITDA margin stood at 27% and PAT margin at 22%. Company’s India branded generic performance exceeds IPM growth by 32%, driven by volumes and new launches.
Financial Performance
Ajanta Pharma announced a strong financial performance for Q2 FY26:
- Revenue from operations: ₹1,354 cr (Up 14%)
- EBITDA: ₹328 cr
- Profit after tax (PAT): ₹260 cr (Up 20%)
Excluding mark-to-market forex loss, EBITDA stood at ₹369 cr with a margin of 27%, while PAT grew by 23%, resulting in a margin of 22%.
Dividend Announcement
The Board of Directors approved an interim dividend of ₹28 per share.
Segment Performance
Here’s a breakdown of revenue by segment:
- Branded Generics: India (₹432 cr), Asia (₹310 cr), Africa (₹221 cr)
- US Generics: ₹344 cr (Up 48%)
Operational Highlights
The company’s India branded generics performance exceeded IPM growth by 32%. Growth in Volumes increased and New Launches also contributed positively.
R&D Expenditure
R&D expenses stood at ₹119 cr for H1 FY26, representing 5% of revenue.
Conference Call Information
Ajanta Pharma will host an earnings conference call on November 3, 2025, at 1500 hrs IST to discuss the financial results.
Source: BSE
